Related references
Note: Only part of the references are listed.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang et al.
LANCET (2020)
Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series
Achille Aouba et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?
Serena Colafrancesco et al.
AUTOIMMUNITY REVIEWS (2020)
Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement
James W. Day et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
Evangelos J. Giamarellos-Bourboulis et al.
CELL HOST & MICROBE (2020)
Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis
George Dimopoulos et al.
CELL HOST & MICROBE (2020)
Use of anakinra in severe COVID-19: A case report
Giovanni Filocamo et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report
Marco Franzetti et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease
Emanuele Pontali et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy
Ning Tang et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Fei Zhou et al.
LANCET (2020)
Covid-19 in Critically Ill Patients in the Seattle Region - Case Series
Pavan K. Bhatraju et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Compassionate Use of Remdesivir for Patients with Severe Covid-19
J. Grein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-Review
Neda Roshanravan et al.
ARCHIVES OF MEDICAL RESEARCH (2020)
Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment
Andres Gonzalez-Garcia et al.
RHEUMATOLOGY (2020)
High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients
Enrique Iglesias-Julian et al.
JOURNAL OF AUTOIMMUNITY (2020)
Role of monoclonal antibody drugs in the treatment of COVID-19
Claudio Ucciferri et al.
WORLD JOURNAL OF CLINICAL CASES (2020)
Anakinra for severe forms of COVID-19: a cohort study
Thomas Huet et al.
LANCET RHEUMATOLOGY (2020)
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study
Giulio Cavalli et al.
LANCET RHEUMATOLOGY (2020)
Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome
Puja Mehta et al.
LANCET RHEUMATOLOGY (2020)
Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome
Luke Adam Monteagudo et al.
ACR OPEN RHEUMATOLOGY (2020)
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial
Bita Shakoory et al.
CRITICAL CARE MEDICINE (2016)
Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials
Laura Campbell et al.
RHEUMATOLOGY (2011)
Share Paper
